Evidence map›Paper›PMID 30979550›Full record

ArticleBiophysical journal2019

Nanobody-CD16 Catch Bond Reveals NK Cell Mechanosensitivity.

Cristina González, Patrick Chames, Brigitte Kerfelec, Daniel Baty, Philippe Robert, Laurent Limozin

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Mechanomedicine.Nature reviews bioengineering · 2026
    Article
  7. Article
  8. Article
  9. Mechanoregulation of lymphocyte cytotoxicity.Nature reviews. Immunology · 2025
    Review
  10. Mechanoimmunological Control of Metastatic Site Selection.bioRxiv : the preprint server for biology · 2025
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Cristina GonzálezAix Marseille Univ, CNRS, INSERM, LAI, Laboratoire Adhesion et Inflammation, Marseille, France.
Patrick ChamesAix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
Brigitte KerfelecAix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
Daniel BatyAix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
Philippe RobertAix Marseille Univ, CNRS, INSERM, LAI, Laboratoire Adhesion et Inflammation, Marseille, France; Laboratoire d'Immunologie, Assistance Publique - Hôpitaux de Marseille, Marseille, France. Electronic address: philippe.robert@inserm.fr.
Laurent LimozinAix Marseille Univ, CNRS, INSERM, LAI, Laboratoire Adhesion et Inflammation, Marseille, France. Electronic address: laurent.limozin@inserm.fr.
Laboratoire Adhésion et inflammation · FRInserm · FRCentre de Recherche en Cancérologie de Marseille · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibodies are key tools in biomedical research and medicine. Their binding properties are classically measured in solution and characterized by an affinity. However, in physiological conditions, antibodies can bridge an immune effector cell and an antigen-presenting cell, implying that mechanical forces may apply to the bonds. For example, in antibody-dependent cell cytotoxicity-a major mode of action of therapeutic monoclonal antibodies-the Fab domains bind the antigens on the target cell, whereas the Fc domain binds to the activating receptor CD16 (also known as FcgRIII) of an immune effector cell, in a quasi-bidimensional environment (2D). Therefore, there is a strong need to investigate antigen/antibody binding under force (2D) to better understand and predict antibody activity in vivo. We used two anti-CD16 nanobodies targeting two different epitopes and laminar flow chamber assay to measure the association and dissociation of single bonds formed between microsphere-bound CD16 antigens and surface-bound anti-CD16 nanobodies (or single-domain antibodies), simulating 2D encounters. The two nanobodies exhibit similar 2D association kinetics, characterized by a strong dependence on the molecular encounter duration. However, their 2D dissociation kinetics strongly differ as a function of applied force: one exhibits a slip bond behavior in which off rate increases with force, and the other exhibits a catch-bond behavior in which off rate decreases with force. This is the first time, to our knowledge, that catch-bond behavior was reported for antigen-antibody bond. Quantification of natural killer cells spreading on surfaces coated with the nanobodies provides a comparison between 2D and three-dimensional adhesion in a cellular context, supporting the hypothesis of natural killer cell mechanosensitivity. Our results may also have strong implications for the design of efficient bispecific antibodies for therapeutic applications.

Indexed as

Mechanical PhenomenaBiomechanical PhenomenaCell AdhesionCell LineHumansKiller Cells, NaturalSingle-Domain AntibodiesSingle-Domain Antibodies

Identifiers

PMID30979550
PMCPMC6486492
OpenAlexW2928801673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.